AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19744006
Drug: D3 receptor
RxNorm normalized name: VITAMIN D3 RECEPTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 receptor subtype-selective agonists
Trial: 12196433
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (40 mU/m2)
Trial: 12196433
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin (40 mU/m2)
Trial: 2673622
Drug: Recainam (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recainam (300 to 600 mg every 8 hours)
Trial: 2673622
Drug: Recainam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recainam (mean effective dosage 427 mg every 8 hours)
Trial: 5420207
Drug: Oxazepam (Serenid-D)
RxNorm normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxazepam (Serenid-D) in green tablets
Trial: 5420207
Drug: Oxazepam (Serenid-D)
RxNorm normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxazepam (Serenid-D) in yellow tablets
Trial: 5420207
Drug: Oxazepam (Serenid-D)
RxNorm normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxazepam (Serenid-D) in red tablets
Trial: 30936281
Drug: Ustekinumab 45
RxNorm normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 45 mg or 90 mg
Trial: 26248573
Drug: Dabigatran Etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran Etexilate 110 mg b.i.d.
Trial: 26248573
Drug: Dabigatran Etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran Etexilate 150 mg b.i.d.
Trial: 14571609
Drug: Shenfu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu injection (SFI) 1.0 ml/kg
Trial: 28029485
Drug: Shenfu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu injection (SFI)
Trial: 11230471
Drug: High-dose L-asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose L-asparaginase (HD ASP) arm; weekly intramuscular administration of HD ASP 25,000 IU/m² for a total of 20 weeks.
Trial: 11230471
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (SD ASP arm).
Trial: 9692708
Drug: K‐Mag (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K‐Mag (70 mmol/day K, 35 mmol/day citrate and 17.6 mmol/day Mg)
Trial: 7908130
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dipyridamole with 1360 mg glutamic acid HCl (achlorhydric subjects)
Trial: 7908130
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dipyridamole without pretreatment (achlorhydric subjects)
Trial: 7908130
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg famotidine (control subjects)
Trial: 7908130
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dipyridamole with 40 mg famotidine (control subjects)
Trial: 7908130
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dipyridamole (both groups)
Trial: 2844492
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of drug and task performance
Trial: 30672252
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with hydro-acupuncture (1 mL Danshen injection per point, 7 days per injection for 2 weeks)
Trial: 30672252
Drug: Regular acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular acupuncture (once a day, six treatments per week for 2 weeks)
Trial: 27427553
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy (TRT) with T gel for 12 weeks, followed by cessation for 8 weeks
Trial: 17051484
Drug: TNF-alpha antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF-alpha antagonists
Trial: 417428
Drug: General supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General supportive treatment
Trial: 10966000
Drug: Four-day infusion
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-day infusion of fluorouracil (1000 mg/m2/day) plus vinorelbine (20 mg/m2/i.v. day 1 and 5), recycled every 3 weeks for a total of six courses.
Trial: 25439417
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of intravenous (IV) melatonin
Trial: 3163527
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gel (1% applied interdentally 4 times/year)
Trial: 3163527
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (applied interdentally 4 times/year)
Trial: 31150753
Drug: Psychosocial family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial family treatments during the first 9 months of the study
Trial: 31150753
Drug: Baseline medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline medication exposure
Trial: 25230094
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (afamelanotide + NB‐UV‐B)
Trial: 25230094
Drug: NB‐UV‐B monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NB‐UV‐B monotherapy
Trial: 21075452
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light treatment (BLT) for 6 weeks (10,000 lux, 30 min daily)
Trial: 9018028
Drug: Sustained-release carbidopa/levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release carbidopa/levodopa (Sinemet CR 50/200)
Trial: 9018028
Drug: Immediate-release carbidopa/levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release carbidopa/levodopa (Sinemet 25/100)
Trial: 3829588
Drug: 70 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mmol/l sucrose
Trial: 3829588
Drug: 140 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mmol/l glucose
Trial: 28108537
Drug: hs-cTnT levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT levels of 9-13 ng/L
Trial: 28108537
Drug: hs-cTnT levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT levels of ≥14 ng/L
Trial: 28108537
Drug: hs-cTnT levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT levels >8 ng/L
Trial: 28108537
Drug: hs-cTnT levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT levels ≤5 ng/L
Trial: 26291092
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment for PAH
Trial: 23147520
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg twice daily for 4 weeks
Trial: 19169168
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of soy protein with 90 mg of isoflavones
Trial: 19169168
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of soy protein without isoflavones
Trial: 19169168
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of milk protein (casein and whey)
Trial: 11431132
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with exogenous estrogen
Trial: 11431132
Drug: Treatment aimed
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment aimed at correcting metabolic abnormalities
Trial: 9208356
Drug: Simvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10 mg daily for 3 months)
Trial: 8215279
Drug: Monthly infusions
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly infusions of immune globulin at a dose of 500 mg/kg of body weight
Trial: 2824045
Drug: Carboplatin (CBDCA)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (CBDCA) 400 mg/m2 iv every 4 weeks until relapse
Trial: 2824045
Drug: Iproplatin (CHIP)
RxNorm normalized name: Aroplatin
DrugBank: Aroplatin (DB17319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iproplatin (CHIP) 270 mg/m2 iv every 4 weeks until relapse
Trial: 28419398
Drug: Ranibizumab (Lucentis;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (Lucentis; Genentech) - first intravitreal injection
Trial: 19404172
Drug: Inpatient physical
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient physical therapy program for 2 weeks
Trial: 15451124
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (TN) with intensive treatment
Trial: 12053057
Drug: Betaxolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol (20 mg)
Trial: 8021483
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of exercise and dietary modification weight-loss programmes
Trial: 2478793
Drug: Pimobendan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan (5 mg b.i.d.)
Trial: 973004
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of prostaglandin F2alpha
Trial: 30782213
Drug: Levothyroxine replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine replacement therapy plus standard chronic heart failure treatment
Trial: 30782213
Drug: Standard chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chronic heart failure therapy
Trial: 28494046
Drug: Implant bed
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implant bed preparation before molar extractions
Trial: 28494046
Drug: Implant bed
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implant bed preparation after molar extractions
Trial: 17244178
Drug: Individual cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive therapy (ICT)
Trial: 16236380
Drug: Fast-food Mediterranean
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-food Mediterranean type diet rich in PAF antagonist
Trial: 1533606
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 mg)
Trial: 3886498
Drug: Aspirin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (2 X 325 mg every 4 h to total 8 tablets during the first 24 h)
Trial: 3886498
Drug: Acetaminophen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (2 X 325 mg every 4 h to total 8 tablets during the first 24 h)
Trial: 3886498
Drug: Placebo (identically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identically packaged, 2 X 325 mg every 4 h to total 8 tablets during the first 24 h)
Trial: 29797212
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin aspart (0.15 unit/kg every two hours)
Trial: 29797212
Drug: Intravenous regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regular insulin (0.05-0.1 unit/kg/hour)
Trial: 24286360
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release melatonin 2 mg (CRM)
Trial: 15863532
Drug: Subcutaneous suture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous suture closure alone
Trial: 12195841
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation powder via Easyhaler (400 micrograms/day)
Trial: 12195841
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation powder via Turbuhaler (400 micrograms/day)
Trial: 9818662
Drug: Low calorie
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calorie diet, appetite suppressant, nonsteroidal antiinflammatory drugs, and walking program for 6 weeks
Trial: 23053376
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no medication
Trial: 20724185
Drug: HRT preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT preparation (2 mg 17β-estradiol, E₂; 1 mg norethisterone acetate, NETA)
Trial: 20724185
Drug: HRT preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT preparation (E₂ or NETA)
Trial: 20724185
Drug: HRT preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT preparation
Trial: 12803592
Drug: Intra-articular saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular saline 10 ml
Trial: 12803592
Drug: Intra-articular saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular saline 10 ml with morphine 2 mg
Trial: 1473916
Drug: Thrombolytic agent
RxNorm normalized name: Thrombolytic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic agent alteplase
Trial: 6464192
Drug: Oltipraz 2
RxNorm normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz 2 X 20 mg/kg
Trial: 6464192
Drug: Praziquantel 2
RxNorm normalized name: praziquantel 23 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 2 X 30 mg/kg
Trial: 6464192
Drug: Oltipraz 1
RxNorm normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz 1 X 25 mg/kg
Trial: 6464192
Drug: Oltipraz 1
RxNorm normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz 1 X 35 mg/kg
Trial: 31381847
Drug: CRA‐melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRA‐melatonin (5 mg)
Trial: 31381847
Drug: IR‐melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR‐melatonin (5 mg)
Trial: 29779247
Drug: POLLINEX® Quattro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POLLINEX® Quattro Plus 1.0 ml Birch 100% (cumulative doses ranging from 5100 to 27300 SU)
Trial: 29779247
Drug: POLLINEX® Quattro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POLLINEX® Quattro Plus 1.0 ml Birch 100% (highest cumulative dose of 27300 SU)
Trial: 29779247
Drug: POLLINEX® Quattro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POLLINEX® Quattro Plus 1.0 ml Birch 100% (various active doses)
Trial: 18852657
Drug: Steroids (S)
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids (S)
Trial: 18852657
Drug: Steroids (S)
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids (S) in hepatitis C virus patients
Trial: 12051959
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) at a dose of 2 g/day
Trial: 12051959
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) at a dose of 4 g/day
Trial: 10192648
Drug: CRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP levels at or above the 97.5th centile (6.17 mg/L)
Trial: 7730940
Drug: Nurse-coordinated intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-coordinated intervention (telephone contacts at least monthly)
Trial: 2292537
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous ciprofloxacin
Trial: 29152243
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for 8 weeks
Trial: 28800861
Drug: Ipatasertib 400
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib 400 mg once per day (days 1-21) plus intravenous paclitaxel 80 mg/m2 (days 1, 8, 15)
Trial: 28800861
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once per day (days 1-21) plus intravenous paclitaxel 80 mg/m2 (days 1, 8, 15)
Trial: 28800861
Drug: Ipatasertib 400
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib 400 mg once per day (days 1-21) plus intravenous paclitaxel 80 mg/m2 (days 1, 8, 15) in PTEN-low population
Trial: 28800861
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once per day (days 1-21) plus intravenous paclitaxel 80 mg/m2 (days 1, 8, 15) in PTEN-low population
Trial: 25457470
Drug: TXA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA (100 mg/Kg loading dose over 20 minutes, followed by 10 mg/Kg/h until skin closure)
Trial: 25457470
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline infusion of similar volume)
Trial: 27841849
Drug: Topical apraclonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical apraclonidine 0.5%
Trial: 22118999
Drug: Oral acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acetazolamide
Trial: 17095879
Drug: No hypotensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hypotensive treatment (control group)
Trial: 7801083
Drug: Shortened i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shortened i.v. treatment duration (1-3 days)
Trial: 3137626
Drug: Pipequaline 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipequaline 50 mg
Trial: 3137626
Drug: Pipequaline 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipequaline 150 mg
Trial: 3137626
Drug: Pipequaline 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipequaline 50 mg + Diazepam 10 mg
Trial: 3137626
Drug: Pipequaline 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipequaline 150 mg + Diazepam 10 mg
Trial: 26990963
Drug: Glucocorticoid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid group (inhaled with Seretide/Pulmicort)
Trial: 21636122
Drug: Dexamethasone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (5 mg once a day for 4 days)
Trial: 21287803
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Cosopt)
Trial: 21287803
Drug: Carbonic anhydrase
RxNorm normalized name: Carbonic anhydrase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbonic anhydrase inhibitors (CAI)
Trial: 16566363
Drug: Transdermal contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal contraceptive system (TCS) with 20 microg ethinyl estradiol (EE) and 150 microg norelgestromin (17‐dNGM)
Trial: 16566363
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive containing 20 microg EE and 150 microg desogestrel
Trial: 11069322
Drug: Tegaserod 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 1 mg/day
Trial: 11069322
Drug: Tegaserod 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 4 mg/day
Trial: 11069322
Drug: Tegaserod 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 1 mg/day and 4 mg/day
Trial: 8117608
Drug: P-100 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-100 administered for ten days following chemotherapy during the first cycle
Trial: 8117608
Drug: P-100 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-100 administered for ten days following chemotherapy during the second cycle
Trial: 28695570
Drug: Monthly mass
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly mass drug administration of dihydroartemisinin-piperaquine
Trial: 28695570
Drug: Bimonthly mass
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimonthly mass drug administration of dihydroartemisinin-piperaquine